Ascendis Pharma A (ASND) Total Non-Current Liabilities (2019 - 2026)

Ascendis Pharma A has reported Total Non-Current Liabilities for 8 years, with the latest figure at $454.9 million in Q1 2026.

• Quarterly Total Non-Current Liabilities rose 18.24% year-over-year to $454.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $454.9 million (up 18.24% YoY) and the FY2025 annual result came in at $461.0 million, up 18.16% from the prior year.
• Total Non-Current Liabilities declined to $454.9 million in Q1 2026 per ASND's latest filing, from $461.0 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $798.9 million in Q3 2023 and troughed at $249.5 million in Q2 2024.
• A 5-year average of $492.4 million and a median of $454.9 million in 2026 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities surged 532.72% in 2022, then tumbled 62.21% in 2023.
• Over 5 years, Total Non-Current Liabilities stood at $668.4 million in 2022, then plunged by 62.21% to $252.6 million in 2023, then soared by 54.44% to $390.1 million in 2024, then grew by 18.16% to $461.0 million in 2025, then fell by 1.32% to $454.9 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $454.9 million, $461.0 million, and $400.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.